Nature Communications (Jun 2018)
Precision therapeutic targeting of human cancer cell motility
- Li Xu,
- Ryan Gordon,
- Rebecca Farmer,
- Abhinandan Pattanayak,
- Andrew Binkowski,
- Xiaoke Huang,
- Michael Avram,
- Sankar Krishna,
- Eric Voll,
- Janet Pavese,
- Juan Chavez,
- James Bruce,
- Andrew Mazar,
- Antoinette Nibbs,
- Wayne Anderson,
- Lin Li,
- Borko Jovanovic,
- Sean Pruell,
- Matias Valsecchi,
- Giulio Francia,
- Rick Betori,
- Karl Scheidt,
- Raymond Bergan
Affiliations
- Li Xu
- Department of Medicine, Northwestern University
- Ryan Gordon
- Division of Hematology/Oncology, Knight Cancer Institute, Oregon Health & Science University
- Rebecca Farmer
- Department of Chemistry, Northwestern University
- Abhinandan Pattanayak
- Division of Hematology/Oncology, Knight Cancer Institute, Oregon Health & Science University
- Andrew Binkowski
- Department of Computer Science, University of Chicago
- Xiaoke Huang
- Department of Medicine, Northwestern University
- Michael Avram
- Department of Anesthesiology, Northwestern University
- Sankar Krishna
- Department of Medicine, Northwestern University
- Eric Voll
- Department of Medicine, Northwestern University
- Janet Pavese
- Department of Medicine, Northwestern University
- Juan Chavez
- Department of Genome Sciences, University of Washington
- James Bruce
- Department of Genome Sciences, University of Washington
- Andrew Mazar
- Department of Chemistry, Northwestern University
- Antoinette Nibbs
- Department of Chemistry, Northwestern University
- Wayne Anderson
- Department of Molecular Pharmacology and Biological Chemistry, Northwestern University
- Lin Li
- Department of Pathology, Northwestern University
- Borko Jovanovic
- Department of Preventive Medicine, Northwestern University
- Sean Pruell
- Department of Medicine, Northwestern University
- Matias Valsecchi
- Department of Medicine, Northwestern University
- Giulio Francia
- Border Biomedical Research Center, University of Texas at El Paso
- Rick Betori
- Department of Chemistry, Northwestern University
- Karl Scheidt
- Department of Chemistry, Northwestern University
- Raymond Bergan
- Division of Hematology/Oncology, Knight Cancer Institute, Oregon Health & Science University
- DOI
- https://doi.org/10.1038/s41467-018-04465-5
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 14
Abstract
In this study, the authors identify and validate a halogen-substituted isoflavanone able to inhibit prostate cancer cell motility, invasion and metastasis in vitro and in vivo. They demonstrate its ability to selectively inhibit activation of client proteins that stimulate cell motility.
